secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001104659-25-079454
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma gets HREC approval for Phase 2 COVID trials of ratutrelvir; top-line data expected year-end 2025
--------------------------------------------------------------------------------

- First Phase 2 non-inferiority trial compares ratutrelvir 600 mg QD for 10 days vs PAXLOVID 5-day regimen in newly diagnosed COVID subjects.
- Second single-arm trial tests ratutrelvir in PAXLOVID-ineligible patients; both trials expect top-line results by year-end 2025.
- Ratutrelvir is ritonavir-free, once-daily for 10 days, aiming to reduce clinical rebound and Long COVID risk.
- Pfizer reported $427M PAXLOVID sales in Q2 2025 (+70% YoY), highlighting continued market need for COVID treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925079454/0001104659-25-079454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925079454/tm2523715d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-079454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer